Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial

Response to Newly Prescribed Lipid-Lowering Therapy in Patients With and Without HIV Infection

(2013) Michael J. Silverberg   ANNALS OF INTERNAL MEDICINE

Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients

(2011) Brian Gazzard et al.   AIDS

Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study)

(2011) D Podzamczer et al.   HIV MEDICINE

Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results

(2011) Paul E. Sax et al.   JOURNAL OF INFECTIOUS DISEASES

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population

(2010) Mark Nelson et al.   AIDS

Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study

(2010) Juan Sierra-Madero et al.   HIV CLINICAL TRIALS

Antiretroviral Treatment of Adult HIV Infection

(2010) Melanie A. Thompson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

(2009) Christine Katlama et al.   AIDS

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

(2009) Anton L Pozniak et al.   AIDS

Effects of First-Line Use of Nucleoside Analogues, Efavirenz, and Ritonavir-Boosted Protease Inhibitors on Lipid Levels

(2009) Andrew Hill et al.   HIV CLINICAL TRIALS

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

(2008)   LANCET